Tuberculosis

Immigrant Medicine

Volumn , Issue , 2007, Pages 255-271

  Bernardo, John ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54949137846     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03454-8.50023-1     Document Type: Chapter

References (37)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163:1009-1021.
2. Trends in Tuberculosis - United States, 2005. MMWR 2006, 55(11):305-308. Centers for Disease Control and Prevention.
3. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005, 54:RR-12. Centers for Disease Control and Prevention., Available: http://www.cdc.gov/nchstp/tb/rtmcc.htm.
4. Wells WF Aerodynamics of droplet nuclei [Chapter 3]. Airborne contagion and air hygiene 1955, Harvard University Press;, Cambridge, MA.
5. Dannenberg AM Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 1989, 11:S369-S378.
6. Flynn JL, Chan J Tuberculosis: latency and reactivation. Infect Immun 2001, 69:4195-4201.
7. Schluger NW Recent advances in our understanding of human host responses to tuberculosis. Respir Res 2001, 2:157-163.
8. Diagnostic standards/classification of TB in adults and children. Am J Respir Crit Care Med 2000, 161:1376-1395. Centers for Disease Control and Prevention/American Thoracic Society.
9. Meyer M, Clarke P, O'Regan AW Utility of the lateral chest radiograph in the evaluation of patients with a positive tuberculin skin test result. Chest 2003, 124:1824-1827.
10. The tuberculin skin test. Am Rev Respir Dis 1981, 124:356-363. American Thoracic Society, Centers for Disease Control.
11. Lee E, Holzman RS Evolution and current use of the tuberculin skin test. Clin Infect Dis 2002, 34:365-370.
12. The role of BCG vaccine in the prevention and control of tuberculosis in the United States (ACET and ACIP). MMWR 1996, 45:RR-4. Centers for Disease Control and Prevention.
13. Pai M, Gokhale K, Joshi R, et al. Mycobacterium tuberculosis infection in healthcare workers in rural India. Comparison of a whole-blood interferon-gamma assay with tuberculin skin testing. JAMA 2005, 293:2746-2755.
14. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005, 293:2756-2761.
15. Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Amer J Respir Crit Care Med 2004, 170:65-69.
16. Guidelines for using the Quanti FERON-TB Gold test for detecting Mycobacterium tuberculosis infection - United States. MMWR 2005, 54:RR-15-RR-55. Centers for Disease Control and Prevention., 49.
17. Daley CL, Gotway MB, Jasmer RM. Radiographic manifestations of tuberculosis. A primer for clinicians. San Francisco, CA: The Francis J. Curry National Tuberculosis Center; 2003. Available: . http://www.nationaltbcenter.edu/catalogue/epub/index.cfm?tableName=RMT).
18. Kent PT, Kubica GP Public health mycobacteriology. A guide for the level III laboratory 1985, CDC;, Atlanta, GA.
19. Catanzaro A, Perry S, Clarridge JE, et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA 2000, 283:639-645.
20. Conaty SJ, Claxton AP, Enoch DA, et al. The interpretation of nucleic acid amplification tests for tuberculosis: do rapid tests change treatment decisions?. J Infect 2005, 50:187-192.
21. Lim TK, Mukhopadhyay A, Gough A, et al. Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. Chest 2003, 124:902-908.
22. Wiener RS, Della-Latta P, Schluger NW Effect of nucleic acid amplification for Mycobacterium tuberculosis on clinical decision making in suspected extrapulmonary tuberculosis. Chest 2005, 128:102-107.
23. Treatment of tuberculosis. MMWR 2003, 52:RR-11. Centers for Disease Control and Prevention.
24. Reported tuberculosis in the United States, 2004 2005, Centers for Disease Control and Prevention., US Department of Health and Human Services;, Atlanta, GA.
25. Goldberg SV, Wallace J, Jackson JC, et al. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004, 8:76-82.
26. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976, 84:181-192.
27. Franks AL, Binkin NJ, Snider DE, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Pub Health Rep 1989, 104:151-155.
28. Nolan CM, Goldberg SV, Buskin SE Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281:1014-1018.
29. Goldberg SV, Wallace J, Jackson JC, et al. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004, 8:76-82.
30. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000, 49:RR-6. Centers for Disease Control and Prevention., 8, Table 2. Available: http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf. Accessed 2/13/07.
31. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005, 54:RR-15-RR-37. Centers for Disease Control and Prevention., 1.
32. Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996, 154:1473-1477.
33. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002, 137:640-647.
34. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR 2002, 51:998-999. Centers for Disease Control and Prevention.
35. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. MMWR 2003, 52(31):735-739. Centers for Disease Control and Prevention.
36. Khan K, Muennig P, Behta M, et al. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002, 347:1850-1859.
37. Preventing and controlling tuberculosis along the US-Mexico Border; Work Group Report. MMWR 2001, 50:RR-1. Centers for Disease Control and Prevention.